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Abstract
Backgrounds  and  aims:  Hepar  lobatum  carcinomatosum  (HLC)  is  an  exceptional  acquired  hepatic
distortion  which  consists  in  irregularly  lobulated  hepatic  contours  seen  in  patients  with  known
liver metastases,  usually  from  breast  carcinoma.  We  aimed  to  describe  and  analyze  ﬁve  similar
cases of  HLC  resulting  from  metastatic  mammary  carcinoma  in  the  liver  and  associated  with
rapid hepatic  failure.
Methods:  Five  cases  of  HLC  were  investigated.  Medical  (including  blood  liver  tests),  radiological
and histological  data  (2  cases)  were  collected  and  retrospectively  analyzed.  All  patients  were
followed  up  for  metastatic  invasive  ductal  carcinoma  of  the  breast  and  had  a  common  pattern  of
treatment with  combination  of  targeted  therapies  (bevacizumab,  AVASTIN)  and  chemotherapy
(paclitaxel,  TAXOL).
Results:  All  the  patients  showed  rapid  hepatic  failure  after  a  mean  of  9  courses  of  beva-
cizumab/paclitaxel.  In  all  cases,  liver  imaging  revealed  liver  capsule  retraction  and  an  irregular
lobular margin.  An  apparent  tumor  regression  of  all  liver  metastases  was  showed  in  two
cases. Biopsies  were  consistent  with  sinusoidal  obstruction  syndrome  (SOS)  and,  surprisingly,  no
tumoral cells  were  found.
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Conclusion:  Although  rare,  such  an  unusual  pattern  of  liver  metastasis  may  mimick  acute  cir-
rhosis and  cause  rapid  hepatic  failure  in  patients,  despite  possible  apparent  tumor  regression  on
imaging.  The  etiology  of  this  pathology  is  unclear,  and  may  involve  multiple  pathogenic  factors.
Direct or  indirect  vascular  injury  plays  an  important  role  in  the  development  of  HLC.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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ibbreviations
LC  Hepar  lobatum  carcinomatosum
MM  Positron  emission  tomography—computed  tomogra-
phy
OS  sinusoidal  obstruction  syndrome
RH  nodular  regenerative  hyperplasia
ntroduction
epar  lobatum  carcinomatosum  (HLC)  is  deﬁned  as  an
cquired  hepatic  distortion  consisting  of  an  irregularly  lobu-
ated  hepatic  contour  seen  in  patients  with  liver  metastases,
sually  from  breast  carcinoma.  Only  a  very  few  cases  have
een  described  in  the  literature  [1—8].  In  this  article,  we
eport  the  largest  series  of  ﬁve  similar  cases  of  HLC  in
atients  treated  for  liver  metastases  from  ductal  breast
arcinoma  and  associated  with  rapid  hepatic  failure.  All
atients  had  a  common  pattern  of  treatment  with  com-
ination  of  targeted  therapies  (bevacizumab,  avastin)  and
hemotherapy  (paclitaxel,  taxol).
ethods
e  identiﬁed  ﬁve  patients  with  HLC  from  April  2013  to  May
014  in  the  database  of  our  imaging  department.  Medical
including  blood  liver  tests),  radiological  and  histological
ata  were  collected  and  retrospectively  analyzed.  This  ret-
ospective  study  had  the  approval  of  our  Research  Ethics
oard  for  chart  review  and  all  patients  provided  written
nformed  consent.
omputed tomography (CT): all the cases
T  scans  were  performed  with  a  16-slice  multidetector  row
elical  CT  scanner  (LightSpeed;  GE  Medical  Systems)  with
.25-mm  collimation  at  120  kV  and  350  mA.  Contiguously
econstructed  sections  were  obtained  through  the  abdomen
n  a  single  breath-hold  with  injection  of  a  contrast  medium.
or  contrast-enhanced  studies,  patients  received  100  mL  of
he  contrast  material  [Iopamiron  370  (Bracco  SpA,  Milan,
taly)  or  Ultravist  370  (Bayer  Schering  Pharma  AG,  Berlin,
ermany)]  at  a  ﬂow  rate  of  2—3  mL/s.
ositron emission tomography—computerized
omography  (PET—CT): case # 2fter  at  least  6  h  of  fasting  and  capillary  glycaemia  mea-
urement  (less  than  2.0  g/L),  we  injected  5  MBq/kg  of
a
i
r8F-FDG  intravenously.  Median  uptake  delay  was  70  min
54—161  min).  Whole-body  PET/CT  images  were  obtained
n  a PET  scanner  Discovery  ST  (General  Electric  Medical
ystem,  Milwaukee,  USA)  in  3D  mode,  without  septa.  CT
ransmission  scans  were  acquired  previously  to  the  PET  scan-
er  for  attenuation  correction,  without  oral  or  intravenous
ontrast  injection,  with  the  constants  of  140  kV/80  mAs  and
lices  of  3.75  mm.
istological analysis: cases # 4 and  5
n  ultrasound,  the  hepatic  parenchyma  displays  impor-
ant  heterogeneous  attenuation,  without  clearly  identiﬁed
ocal  mass.  We  decided  to  perform  percutaneous  non-
argeted  needle  biopsies  under  ultrasonographic  guidance
sing  an  18-Gauge  needle,  according  to  the  recommenda-
ions  of  the  American  Association  for  the  Study  of  Liver
iseases.  There  was  no  contraindication  at  the  time  of
he  biopsies.  Three  cores  of  liver  tissue  were  obtained
n  each  patient.  The  biopsy  specimens  were  processed
nd  parafﬁn  sections  were  stained  with  HES,  Masson’s
richrome,  Perls.  An  immunochemistry  study  was  performed
ith  anti-Pancytokeratin  antibody  (AE1/AE3/PCK26  clone,
entana-760-2135,  revealed  with  ultraView  universal  DAB
etection  kit,  on  Ventana  Benchmark  Ultra  staining  sys-
em).  For  the  remaining  patients,  percutaneous  biopsies
ere  avoided  due  to  the  risk  of  haemorrhage.  Trans-jugular
iopsies  were  also  not  possible  (refusal  for  patients  #1  and
3,  lack  of  cooperation  for  patient  #2).
esults
linical ﬁndings
his  study  included  ﬁve  female  patients  with  a  mean  age  of
1  years  (range  56—69),  diagnosed  from  April  2013  to  Jan-
ary  2014.  The  patients  were  followed  up  for  metastatic
nvasive  ductal  carcinoma  of  the  breast  (grade  III  for  cases
1,2  and  4,  grade  II  for  cases  #3  and  5)  with  metachronous
iver  metastases,  treated  by  the  combination  of  targeted
herapies  (bevacizumab,  avastin)  and  chemotherapy  (pacli-
axel,  taxol).
Patients  #1,  #2,  #3,  #4  and  #5  were  admitted  for
ajor  asthenia  after  6,  10,  9,  10  and  8  courses  of
evacizumab/paclitaxel,  respectively.  Physical  examination
howed  hepatomegaly  and  signs  of  hepatocellular  failure,
ncluding  mainly  hepatic  encephalopathy,  stellar  angiomas
nd  palmar  erythrosis  in  all  patients;  jaundice  was  noticed
n  patients  #1,  2,  4  and  5.  In  case  #1,  gastric  ﬁbroscopy
evealed  oesophageal  varices  (grade  I/II).
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Biological results
Last  blood  tests  revealed  thrombocytopenia  and  liver  tests
showed  decreased  factor  ﬁve  (42,  58,  30,  50  and  56,  respec-
tively)  associated  with  low  prothrombin  ratio  (45,  57,  35,  52
and  48%,  respectively),  increased  serum  levels  of  bilirubin
(40,  36,  38,  45  and  38  mol/L,  respectively),  glutamyl-
transpeptidase,  alkaline  phosphatase,  aspartate  and  alanine
aminotransferases.  The  mean  level  of  CA  15-3  was  810  U/mL
(1673,  1179,  360,  268  and  28  for  cases  #1,  #2,  #3,  #4,  #5,
respectively)  (normal  range  <  25  U/mL).
There  was  no  clinical  or  serological  evidence  for  hepatitis
B  or  C  virus  infection,  autoimmune  hepatitis,  Wilson’s  dis-
ease,  or  hemochromatosis;  moreover,  there  was  no  history  of
alcohol  or  drug  consumption.  Syphilis  serum  tests,  including
venereal  disease  research  laboratory  test;  treponema  pal-
lidum  hemagglutination  assay;  and  ﬂuorescent  treponemal
antibody  absorption  test  were  also  negative.
Imaging ﬁndings
In  all  cases,  CT  scans  revealed  a  heterogeneous  liver
parenchyma,  with  major  capsular  retractions  that  had
not  been  detected  on  previous  scans  (performed  less
than  3  months  before  radiological  diagnosis  in  all  cases)
(Figs.  1—3).  The  retractions  were  more  signiﬁcant  on  sites  of
metastases  (case  #4,  Fig.  3).  Imaging  revealed  an  apparent
tumor  regression  of  all  liver  metastases  in  cases  #3  and  4,
whereas  in  cases  #1,  #2  and  #5,  lesions  were  stable.  Partial
portal  vein  thrombosis  appeared  in  case  #1;  suprahepatic
veins  were  patent.  While  moderate  ascites  were  found  in  all
patients,  patent  para-umbilical  vein  was  only  seen  in  case
#3.  No  splenomegaly  was  found.  Regional  changes  included
segmental  hypertrophy  involving  the  lateral  segments  (II,  III)
of  the  left  lobe  in  all  cases,  and  caudate  lobe  hypertrophy
D
I
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Figure 1. Case #3, CT scans. A. A 59-year-old patient with liver metasta
breast. B and C. Two months later, CT scan revealed large capsular retra
vein (white arrow). The patient died of hepatic failure 3 weeks later. from  breast  cancer  75
nd  central  atrophy  in  cases  #1  and  3.  Patients  #3  and  #5
resented  a  stable  disease,  whereas  patients  #1,  2  and  4
uffered  from  metastatic  progression  to  bone  (case  #1)  and
ung  sites  (cases  #2  and  #4).
In  case  #2,  PET—CT  showed  an  intense  accumulation  of
8F-FDG  in  sub-capsular  regions  two  months  before  capsular
etractions  and  regional  changes  (Fig.  2).
athological results
ercutaneous  biopsies  were  performed  in  only  two  patients
cases  #4  and  #5).  Interestingly,  no  tumor  inﬁltration  was
evealed  by  microscopic  and  immunochemistry  study,  both
n  the  parenchyma  and  in  the  vascular  structures.  The
epatocyte  plates  appeared  disrupted  irregularly  widened,
eaching  an  aspect  of  diffuse  nodular  regenerative  hyper-
lasia  (NRH).  These  plates  were  separated  by  angulous
nd  patchy  dilatated  sinusoid  capillaries;  the  endothelial
ells  boarding  these  sinusoids  were  focally  hyperplasic.
ew  erythrocytes  were  spilled  between  hepatocytes.  Cen-
rilobular  veins,  portal  areas  and  bile  ducts  were  without
istological  peculiarities,  and  no  ﬁbrosis  was  observed.  All
hese  aspects  were  consistent  with  sinusoidal  obstruction
yndrome  (SOS)  (Fig.  4).
utcome and follow-up
ll  ﬁve  patients  died  of  liver  failure  within  4  weeks  of  being
iagnosed  with  HLC.iscussion
n  this  paper,  we  describe  the  largest  series  of  HLC  in
atients  treated  for  liver  metastases  from  ductal  breast
ses (black arrows) secondary to an invasive ductal carcinoma of the
ction associated with moderate ascites and patent para-umbilical
76  N.  Alberti  et  al.
Figure 2. Case #1. A. Non-enhanced CT scan of a 56-year-old patient with liver metastases secondary to an invasive ductal carcinoma of
the breast. B. PET scan revealed an intense uptake of the sub-scapular areas. C and D. Two months later, CT scan showed large capsular
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metraction and regional changes, including hypertrophy of caudate lo
f hepatic failure 4 weeks later.
arcinoma  with  combination  of  targeted  therapies  (beva-
izumab,  avastin)  and  chemotherapy  (paclitaxel,  taxol).  All
ve  patients  died  of  acute  liver  failure  within  4  weeks  of
eing  diagnosed  with  HLC.
First  described  in  tertiary  syphilitic  liver  [1],  HLC,  also
nown  as  ‘‘liver  pseudocirrhosis’’  is  often  associated  with
nvasive  ductal  and  lobular  breast  carcinoma  [2—5].  Liver
f
S
c
igure 3. Case #5. A. A 69-year-old patient with liver metastases secon
ater, ﬁrst retractions occurred, mainly at sites of metastases. An appar
onths later, these retractions increased signiﬁcantly. The patient died hite arrow). Moderate ascites was also observed. The patient died
etastases  from  the  kidney,  stomach,  nasopharynx  cancers
ave  also  been  associated  to  that  pathology  [6]  and,  in  some
are  cases,  HLC  may  reveal  the  primitive  neoplasm  [3].The  pathogenesis  of  HLC  is  unclear  and  probably  multi-
actorial.  On  biopsies,  we  found  similar  lesions  relative  to
OS.  Early  studies  supported  the  hypothesis  that  metastatic
ell  invasion  provokes  a  desmoplastic  stromal  reaction.  In
dary to an invasive ductal carcinoma of the breast. B. Three months
ent tumor regression of all liver metastases was observed. C. Two
of hepatic failure 3 weeks later.
Hepar  lobatum  carcinomatosum  associated  with  liver  metastases
Figure 4. Case #5, pathology. Percutaneous biopsies were per-
formed in patient #5. A. Patchy periveinular sinusoidal dilatation
(black arrows) and congestion associated with hyperplasic endothe-
lial cells, sometimes unsticked from space of Disse, were observed.
Interestingly, nor tumor inﬁltration or ﬁbrosis were noticed.
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ReferencesB. Showed a typical aspect of diffuse NRH (asterisks). All these
lesions were consistent with SOS.
several  cases,  direct  invasion  and  occlusion  of  intrahepatic
vessels,  mostly  portal  and  sinusoidal,  by  tumor  cells  have
been  observed  [7—10].  However,  in  our  2  cases,  the  strik-
ing  microscopic  ﬁnding  was  areas  of  sinusoidal  dilatation
which  did  not  show  any  occlusion  by  tumor  emboli.  This
vascular  injury  would  be  responsible  for  a  heterogeneous
liver  perfusion  with  atrophy  of  the  invaded  liver  segments
and  compensatory  hypertrophy  [5,6].  Many  chemother-
apy  drugs,  including  alkylating  agents  (cyclophosphamide),
anti-metabolites  (methotrexate,  5-FU),  cytotoxic  antibi-
otics  (doxorubicin,  epirubicin,  mitomycin,  mitoxanthrone)
and  plant  alkaloids  (vinblastine,  paclitaxel,  docetaxel)  have
been  associated  to  SOS  [3,8—10].  In  our  patients,  capsu-
lar  retractions  on  CT  were  detected  after  a  mean  of  eight
courses  of  bevacizumab  (avastin)/paclitaxel  (taxol).  Thus,
even  though  the  dose  was  within  the  ordinary  range  used
to  treat  breast  cancer,  it  seems  likely  that  this  combination
chemotherapy  played  a  role  in  the  development  of  HLC.  A
weakness  of  our  study  is  the  lack  of  percutaneous  biopsies,
which  we  avoided  due  to  major  hemorrhagic  risks  associ-
ated  with  hepatic  failure  in  three  patients.  However,  it  is
likely  that  such  lesions  would  have  been  found  in  the  liver
of  the  remaining  patients  (similar  cases:  age;  type  of  cancer;
clinical,  biological  and  radiological  ﬁndings).
Liver  imaging  made  the  diagnosis  in  all  the  cases,  show-
ing  major  liver  capsule  retraction  and  an  irregular  lobular
margin  with  crevices  and  linear  depression.  Segmental  vol-
ume  loss  and  caudate  lobe  enlargement  were  observed,  as
in  cirrhosis,  in  cases  #1  and  3.  As  previously  described, from  breast  cancer  77
etraction  occurred  mainly  at  sites  of  metastases  [5].  Signs
f  portal  hypertension  are  frequently  observed  in  HLC,  as  in
ase  #3  (patent  para-umbilical  vein).  Interestingly,  in  case
2,  PET—CT  showed  an  intense  sub-capsular  uptake  two
onths  before  capsular  retractions  and  regional  changes.
o  our  knowledge,  this  aspect  has  never  been  reported  in
he  literature  before.  MRI  may  also  be  useful  to  support
his  diagnosis,  showing  large  ﬁbrous  bands  on  delayed-phase
eﬁning  the  pseudo-nodules  occurs  at  initial  sites  of  metas-
ases  [5].
Drug-induced  liver  injury  presents  with  extremely
iverse  histological  patterns,  including  necro-inﬂammatory,
holestatic,  steatotic  and  vascular  patterns.  SOS  also
eferred  to  as  toxic  sinusoidal  injury,  veno-occlusive  dis-
ase  or  ‘‘blue  liver  syndrome’’,  is  a  commonly  recognized
ascular  pattern  of  drug-induced  liver  injury  [7].  For  the
athologists,  it  is  characterized  by  the  loss  of  sinusoidal
all  integrity  with  sinusoidal  congestive  obstruction,  and
aybe  associated  with  peri-sinusoidal  ﬁbrosis,  centrilobu-
ar  hepatic  vein  ﬁbrotic  obstruction,  nodular  regenerative
yperplasia  (HNR),  or  peliosis.
In  the  literature,  different  therapeutic  approaches  were
dopted  to  treat  HLC,  namely,  chemotherapy  or  hor-
onotherapy;  however,  the  survival  of  the  reported  cases
ever  exceeded  a  few  months  [11].
onclusion
o  conclude,  we  describe  ﬁve  cases  of  an  uncommon
iver  dysmorphy  resulting  from  liver  metastases  of  breast
arcinoma  treated  with  the  combination  of  bevacizumab
avastin)  and  paclitaxel  (taxol).  Such  an  unusual  pattern
f  liver  metastasis  may  mimick  cirrhosis  and  cause  rapid
epatic  failure  in  patients,  despite  apparent  tumor  regres-
ion  on  imaging.  This  observation  suggests  that:
direct  or  indirect  vascular  injury  plays  an  important  role
in  the  development  of  HLC;
HLC  may  arise  as  a  particular  form  of  healing  and  scarring
after  tumor  regression,  as  previously  mentioned  [2,3];
the  administration  of  this  particular  combination  played
a  role  in  the  development  of  this  affection  in  our  cases
[3,4].
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